HSDT vs. NDRA, NUWE, TIVC, BSGM, STRR, NRXS, QTI, ENSC, KZIA, and ARTL
Should you be buying Helius Medical Technologies stock or one of its competitors? The main competitors of Helius Medical Technologies include ENDRA Life Sciences (NDRA), Nuwellis (NUWE), Tivic Health Systems (TIVC), BioSig Technologies (BSGM), Star Equity (STRR), NeurAxis (NRXS), QT Imaging (QTI), Ensysce Biosciences (ENSC), Kazia Therapeutics (KZIA), and Artelo Biosciences (ARTL).
ENDRA Life Sciences (NASDAQ:NDRA) and Helius Medical Technologies (NASDAQ:HSDT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, community ranking, earnings, analyst recommendations and dividends.
In the previous week, Helius Medical Technologies had 3 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 3 mentions for Helius Medical Technologies and 0 mentions for ENDRA Life Sciences. Helius Medical Technologies' average media sentiment score of 0.00 equaled ENDRA Life Sciences'average media sentiment score.
ENDRA Life Sciences has a net margin of 0.00% compared to ENDRA Life Sciences' net margin of -1,374.22%. Helius Medical Technologies' return on equity of -197.36% beat ENDRA Life Sciences' return on equity.
Helius Medical Technologies has a consensus price target of $54.50, suggesting a potential upside of 990.00%. Given ENDRA Life Sciences' higher probable upside, analysts plainly believe Helius Medical Technologies is more favorable than ENDRA Life Sciences.
Helius Medical Technologies has higher revenue and earnings than ENDRA Life Sciences. Helius Medical Technologies is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.
ENDRA Life Sciences has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Helius Medical Technologies has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.
ENDRA Life Sciences received 215 more outperform votes than Helius Medical Technologies when rated by MarketBeat users. Likewise, 62.67% of users gave ENDRA Life Sciences an outperform vote while only 57.14% of users gave Helius Medical Technologies an outperform vote.
1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 18.6% of Helius Medical Technologies shares are owned by institutional investors. 4.8% of ENDRA Life Sciences shares are owned by insiders. Comparatively, 7.3% of Helius Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Helius Medical Technologies beats ENDRA Life Sciences on 9 of the 15 factors compared between the two stocks.
Get Helius Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSDT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HSDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Helius Medical Technologies Competitors List
Related Companies and Tools
